Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) – Pipeline Review, H1 2017’, provides in depth analysis on Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas

Oncology under development targeting Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)

– The report reviews Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)targeted therapeutics and enlists all their major and minor projects

– The report assesses Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

AstraZeneca Plc

BeiGene Ltd

Clovis Oncology Inc

Eisai Co Ltd

Ildong Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tesaro Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphttheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Overview

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

BeiGene Ltd

Clovis Oncology Inc

Eisai Co Ltd

Ildong Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tesaro Inc

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Drug Profiles

ABT-767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-0108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1775 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-6738 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGBA-317 + BGB-290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niraparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rucaparib camsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-10914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-3162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOMCL-9112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YHP-743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Dormant Products

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Discontinued Products

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC

2.4.2.30) - Product Development Milestones

Featured News & Press Releases

May 23, 2017: Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting

May 12, 2017: McKesson Specialty Health Selected by TESARO to provide ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

May 11, 2017: TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer

Apr 24, 2017: Biologics Selected by TESARO as a Specialty Pharmacy Provider for ZEJULATM (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

Apr 21, 2017: BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting

Apr 19, 2017: Diplomat Will Dispense ZEJULA to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Apr 19, 2017: TESARO Announces Availability of Zejula (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.

Apr 19, 2017: US Bioservices selected by TESARO to dispense ZEJULA

Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer

Mar 28, 2017: AstraZeneca shares progress on LYNPARZA (olaparib) tablets in the US

Mar 28, 2017: Clovis Oncology Announces Data Presentations At AACR Annual Meeting 2017

Mar 28, 2017: Eisai to Present Data on E7449 at 2017 AACR Annual Meeting

Mar 27, 2017: TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer

Mar 27, 2017: Tesaro Announces U.S. FDA Approval Of Zejula (Niraparib) For Women With Recurrent Ovarian Cancer

Mar 14, 2017: Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by AbbVie Inc, H1 2017

Pipeline by AstraZeneca Plc, H1 2017

Pipeline by BeiGene Ltd, H1 2017

Pipeline by Clovis Oncology Inc, H1 2017

Pipeline by Eisai Co Ltd, H1 2017

Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2017

Pipeline by Tesaro Inc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports